Cardium Therapeutics, Inc. And Aries Ventures Announce Appointment Of Tyler M. Dylan As Chief Business Officer And General Counsel

SAN DIEGO, Nov. 16 /PRNewswire-FirstCall/ -- Cardium Therapeutics Inc. and its parent Aries Ventures Inc. announced the appointment of Tyler M. Dylan, Ph.D., J.D. as Executive Vice President, Chief Business Officer and General Counsel. Under the appointment, which was effective as of October 20, 2005 when Cardium Therapeutics merged with a specially formed subsidiary of Aries Ventures, he will also serve as corporate secretary of both Cardium Therapeutics and Aries Ventures.

(Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)

Dr. Dylan has more than fifteen years of experience in legal and transactional matters related to the development of biological products, including more than seven years focused on the development of cardiovascular growth factor therapeutics. Dr. Dylan served as Vice President and General Counsel of Collateral Therapeutics, which was acquired by Schering AG Germany in 2002, and he was subsequently a co-founder of Cardium Therapeutics. Prior to joining Collateral in 1998, Dr. Dylan was a partner with the law firm of Morrison & Foerster LLP where he specialized in intellectual property and related business and transactional matters. Dr. Dylan received a B.Sc. in Molecular Biology from McGill University, Montreal, Canada; a Ph.D. in Biology from the University of California, San Diego (UCSD Center for Molecular Genetics); and a J.D. from the University of California, Berkeley (Boalt Hall).

Christopher J. Reinhard, Chairman and Chief Executive Officer of Cardium Therapeutics and Aries Ventures stated, "Tyler and I worked together at Collateral Therapeutics for over a half decade. During that time, Tyler played an important role in advancing Collateral's intellectual property position and corporate development activities, which led to Schering AG's acquisition of Collateral in 2002. Subsequently, Tyler and I co-founded Cardium Therapeutics and I look forward to working with him as we seek to accelerate the commercial development of our lead product candidate, Generx, and our other programs."

About the Company

Cardium Therapeutics Inc. and its parent Aries Ventures, Inc. (the Company), headquartered in San Diego, are primarily focused on interventional cardiology and the development and commercialization of non-surgical cardiovascular gene therapeutics. The Company's lead product candidate, Generx(TM), is a non-surgical angiogenic therapy designed to be a one-time treatment for patients with recurrent angina due to coronary artery disease. Generx and the related cardiovascular technology platform were pioneered by Collateral Therapeutics, a San Diego-based biotechnology company co-founded by Cardium's CEO Christopher Reinhard. In 1996, Schering AG Germany and Collateral Therapeutics entered into a strategic partnership to develop angiogenic DNA-based therapeutics, including Generx. Based on the advancing clinical progress of Generx, Schering AG acquired Collateral Therapeutics in 2002. In October 2005, Cardium Therapeutics announced the acquisition of a portfolio of cardiovascular growth factor therapeutics from Schering AG Germany, including the later-stage product candidate, Generx, and simultaneously merged with a specially formed subsidiary of Aries Ventures Inc. and completed a $30 million financing. For more information about the company and its product candidates, please visit www.cardiumthx.com.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. For example, there can be no assurance that critical personnel can be retained, that our efforts to accelerate the commercial development of our lead product will be successful, that required clinical trials will be successful, that necessary regulatory approvals will be obtained or that the proposed treatments will prove to be safe or effective. Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, our limited experience in the development of DNA-based cardiovascular therapeutics, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in our filings with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof.

Copyright 2005 Cardium Therapeutics, Inc. All rights reserved. Terms of Use Privacy Policy. Cardium Therapeutics(TM) and Generx(TM) are trademarks of Cardium Therapeutics, Inc.

CONTACT: Press / Investors, Bonnie Ortega, Director, Investor Relations ofCardium Therapeutics Inc., +1-858-436-1018,InvestorRelations@cardiumthx.com

Web site: http://www.cardiumthx.com/